Vitamin D Boosts Breast Cancer Chemotherapy Success by 79% – UNESP Study Reveals

A recent randomized clinical trial conducted at Brazil's Botucatu School of Medicine has revealed that a simple daily supplement of vitamin D can significantly enhance the effectiveness of chemotherapy for breast cancer patients. In this phase II study, women receiving neoadjuvant chemotherapy—treatment administered before surgery to shrink tumors—saw their chances of achieving a pathological complete response, where no detectable cancer remains, increase dramatically. This finding positions vitamin D as a potential low-cost adjunct to standard therapies, sparking interest across global academic circles.

The trial's results underscore the intersection of nutritional science and oncology, highlighting how optimizing vitamin D levels could improve patient outcomes. As breast cancer remains one of the most prevalent malignancies worldwide, affecting millions annually, such discoveries from university-led research hold promise for refining treatment protocols.

🔬 Unpacking the UNESP Clinical Trial

The study, published in the journal Nutrition and Cancer, involved 80 women over the age of 45 diagnosed with breast cancer and preparing for neoadjuvant chemotherapy at the Hospital das Clínicas outpatient clinic. Participants were randomized into two groups: one received 2,000 international units (IU) of vitamin D daily, while the other took placebo tablets. Both groups underwent standard chemotherapy regimens over six months.

At the trial's conclusion, 43 percent of the vitamin D group achieved pathological complete response (pCR), compared to just 24 percent in the placebo group. This relative increase of 79 percent in treatment success marks a substantial advancement. Notably, most participants started with vitamin D deficiency, defined as serum levels below 20 nanograms per milliliter (ng/mL), which rose steadily in the supplemented group.

Lead researcher Eduardo Carvalho-Pessoa, also president of the São Paulo Regional Brazilian Society of Mastology, emphasized the accessibility of this approach: the dosage used was modest, far below typical correction levels for deficiency, yet yielded clear benefits.

Neoadjuvant Chemotherapy Explained

Neoadjuvant chemotherapy, or neoadjuvant systemic therapy (NST), involves delivering powerful drugs like anthracyclines and taxanes prior to surgical intervention. The goal is to reduce tumor size, eliminate microscopic disease, and assess treatment responsiveness. Pathological complete response (pCR) serves as a key endpoint, correlating strongly with long-term survival, particularly in hormone receptor-positive or triple-negative breast cancers.

In step-by-step terms: patients first undergo biopsy and imaging to stage the cancer. Chemotherapy cycles—typically every two to three weeks—are administered intravenously. Midway assessments via MRI or ultrasound guide adjustments. Post-treatment surgery removes residual tumor, with pathology confirming pCR if no invasive cancer cells remain in breast or lymph nodes.

This university-driven trial adds to evidence that supportive interventions can amplify these effects without added toxicity.

How Vitamin D Interacts with Cancer Cells

Vitamin D, technically cholecalciferol (vitamin D3) or ergocalciferol (D2), requires activation in the liver and kidneys to form calcitriol, its active hormone form. This binds to vitamin D receptors (VDR) on cells, influencing gene expression.

In breast cancer contexts, vitamin D promotes apoptosis (programmed cell death), inhibits proliferation, angiogenesis (new blood vessel formation), and metastasis. It enhances chemotherapy sensitivity by upregulating proteins like p21 and downregulating anti-apoptotic Bcl-2. Preclinical models show synergy with drugs like doxorubicin and paclitaxel, explaining the observed pCR boost.

• Reduces inflammation via cytokine modulation.
• Supports immune surveillance through T-cell activation.
• Regulates estrogen signaling in hormone-dependent tumors.

Deficiency, common in 40-90 percent of cancer patients due to poor sun exposure, malabsorption, or treatment effects, may undermine these benefits.

Botucatu School of Medicine: A Hub of Oncology Innovation

São Paulo State University (UNESP), one of Brazil's top public institutions, hosts the Botucatu School of Medicine (FMB-UNESP), renowned for translational research. With over 1,000 faculty and a focus on public health, FMB-UNESP integrates clinical care, teaching, and discovery at its Hospital das Clínicas, serving underserved populations.

The trial received funding from FAPESP, São Paulo's research agency, exemplifying how state support fuels higher education breakthroughs. UNESP ranks highly in Latin American university standings, particularly in medicine and pharmacology, fostering collaborations with global partners like the NIH and European consortia.

This vitamin D study exemplifies FMB-UNESP's commitment to affordable interventions amid Brazil's high breast cancer burden—over 70,000 new cases yearly.

Key Researchers Driving the Discovery

The multidisciplinary team included Michelle Sako Omodei, Jackeline Chimicoviaki, Daniel Araujo Brito Buttros, Benedito Souza Almeida-Filho, Carla Priscila Carvalho-Pessoa, Eduardo Carvalho-Pessoa, Heloisa De Luca Vespoli, and Eliana Aguiar Petri Nahas. Their expertise spans oncology, endocrinology, and nutrition, reflecting collaborative academic training.

Eduardo Carvalho-Pessoa noted, "These results justify larger studies to deepen our understanding of vitamin D's role." Such work highlights career paths in university hospitals, blending patient care with rigorous trials.

Prior Research Supporting Vitamin D's Role

Building on decades of evidence, earlier studies like a 2018 French retrospective analysis linked sufficient vitamin D to higher pCR rates. A 2021 phase II trial in Europe corrected deficiencies during adjuvant chemo, reducing bone loss.

Meta-analyses indicate 20-35 percent risk reductions in progression for replete patients. U.S. trials at institutions like Vanderbilt explored high-dose protocols, while Asian universities examined genetic VDR polymorphisms influencing response.

These converge on a consensus: maintaining 30-50 ng/mL optimizes outcomes, informing guidelines from the American Society of Clinical Oncology.

Challenges: Vitamin D Deficiency in Cancer Patients

Up to 80 percent of breast cancer patients present deficient at diagnosis, exacerbated by chemotherapy-induced malabsorption and lifestyle factors. In Brazil, urban living limits sunlight, the primary source alongside fortified foods and supplements.

Testing involves serum 25-hydroxyvitamin D; insufficiency (20-30 ng/mL) warrants monitoring. Risks of excess are rare below 10,000 IU daily, but hypercalcemia requires vigilance.

• Seasonal variations in temperate climates.
• Obesity sequesters vitamin D in fat.
• Renal impairment hampers activation.

Implications for Global Breast Cancer Treatment

If validated, vitamin D could democratize enhanced chemo response, especially in low-resource settings. Costing pennies daily, it outperforms pricier sensitizers. For HER2-negative subtypes prevalent in trials, integration into protocols might elevate cure rates.

Stakeholders—patients, oncologists, policymakers—welcome adjuncts reducing recurrence by proxy of pCR. Insurers eye savings from fewer surgeries or advanced therapies. ScienceDaily coverage amplifies academic impact.

Future Outlook: Larger Trials and Beyond

Researchers advocate phase III trials with diverse cohorts, including younger patients and ethnic variations. Ongoing at UNESP and partners, these will probe optimal dosing, combinations with immunotherapy, and biomarkers predicting responders.

Timeline: interim data by 2028, guidelines updates by 2030. Higher education's role amplifies via training fellows in trial design and biostatistics.

Photo by Sasun Bughdaryan on Unsplash

Careers in Oncology Research at Universities

This breakthrough illustrates vibrant opportunities in higher education. Postdocs at institutions like UNESP analyze trial data, advancing to professorships. Faculty secure grants for vitamin D-cancer labs, mentoring students in clinical trials.

Global demand surges for experts in nutraceuticals-oncology, with roles in pharma-university partnerships. Salaries average $100,000-$200,000, plus impact on lives.